Literature DB >> 12483006

Osteonecrosis of the hip in patients with aplastic anemia.

Jeongmi Park1, Jeongsu Jun, Yongsik Kim, Jongwook Lee, Chunchu Kim, Seongtae Hahn.   

Abstract

The incidence and clinical and magnetic resonance imaging features of osteonecrosis of the hip were evaluated in patients with aplastic anemia. Two hundred and forty-one patients with aplastic anemia were examined using MR imaging of bone marrow during the five years from 1994 to 1998. Osteonecrosis of the hip was observed on MR imaging in nineteen (15 males and 4 females, mean age 35 yr) of the 241 patients. It was present in both hips in 14 patients, and there were five cases with unilateral occurrence, with a total of 33 involved hips. All except for five hips with associated bone marrow edema revealed increased fatty marrow conversion in the proximal femoral metaphysis. In nine patients, osteonecrosis was detected without any pain. Five patients already had osteonecrosis before any medication was administered. Twelve patients received antilymphocyte globulin, and seven patients received a low dose of steroids before the MR diagnosis of osteonecrosis. Osteonecrosis of the hip frequently develops in patients with aplastic anemia (7.9%), associated with fatty marrow conversion of the proximal femoral metaphysis.

Entities:  

Mesh:

Year:  2002        PMID: 12483006      PMCID: PMC3054964          DOI: 10.3346/jkms.2002.17.6.806

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  5 in total

Review 1.  [Skeletal manifestations of systemic hematologic disorders].

Authors:  J Luitjens; A Baur-Melnyk
Journal:  Radiologe       Date:  2021-11-24       Impact factor: 0.635

Review 2.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

3.  Prevalence of osteonecrosis and associated risk factors in children before allogeneic BMT.

Authors:  S Sharma; S Yang; R Rochester; L Britton; W H Leung; J Yang; M D Neel; K K Ness; S C Kaste
Journal:  Bone Marrow Transplant       Date:  2010-09-06       Impact factor: 5.483

4.  Rationale for prostaglandin I2 in bone marrow oedema--from theory to application.

Authors:  Marcus Jäger; Frank Peter Tillmann; Thomas S Thornhill; Marcus Mahmoudi; Dirk Blondin; Gerd Rüdiger Hetzel; Christoph Zilkens; Rüdiger Krauspe
Journal:  Arthritis Res Ther       Date:  2008-10-03       Impact factor: 5.156

5.  Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.

Authors:  André Tichelli; Régis Peffault de Latour; Jakob Passweg; Cora Knol-Bout; Gérard Socié; Judith Marsh; Hubert Schrezenmeier; Britta Höchsmann; Andrea Bacigalupo; Sujith Samarasinghe; Alicia Rovó; Austin Kulasekararaj; Alexander Röth; Dirk-Jan Eikema; Paul Bosman; Peter Bader; Antonio Risitano; Carlo Dufour
Journal:  Haematologica       Date:  2019-10-03       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.